The Journal of Practical Medicine ›› 2024, Vol. 40 ›› Issue (5): 702-707.doi: 10.3969/j.issn.1006-5725.2024.05.019
• Investigations • Previous Articles Next Articles
Wenji ZHUO1,Ran WEI1,Yanmei CHEN1,Xunxun CHEN1,Meiling YU1,Huixin GUO1,Hongdi LIANG1,Jing LIANG2,Xiaoyu. LAI1()
Received:
2023-11-03
Online:
2024-03-10
Published:
2024-03-26
Contact:
Xiaoyu. LAI
E-mail:871995770@qq.com
CLC Number:
Wenji ZHUO,Ran WEI,Yanmei CHEN,Xunxun CHEN,Meiling YU,Huixin GUO,Hongdi LIANG,Jing LIANG,Xiaoyu. LAI. Drug resistance characteristics and treatment strategies of TB patients in three age groups in Guangdong Province from 2014 to 2020[J]. The Journal of Practical Medicine, 2024, 40(5): 702-707.
Tab.1
Drug resistance of MTB clinical isolates to 9 anti-tuberculosis drugs in each year"
年份 | 耐INH | 耐Sm | 耐EMB | 耐RFP | 耐Km | 耐Pto | 耐Cm | 耐Ofx | 耐PAS |
---|---|---|---|---|---|---|---|---|---|
合计 | 4 333(11.0) | 6 320(16.1) | 2 748(7.0) | 2 750(6.9) | 1 143(2.9) | 1 579(4.0) | 1 253(3.2) | 1 698(4.3) | 1 499(3.8) |
2014 | 376(13.1) | 531(18.5) | 239(8.3) | 205(7.1) | 116(4.0) | 100(3.5) | 108(3.7) | 162(5.6) | 111(3.8) |
2015 | 582(11.7) | 699(14.1) | 297(6.0) | 362(7.3) | 138(2.7) | 202(4.0) | 153(3.0) | 263(5.3) | 172(3.4) |
2016 | 688(11.3) | 1 058(17.3) | 422(6.9) | 366(6.0) | 208(3.4) | 217(3.5) | 220(3.6) | 310(5.0) | 214(3.5) |
2017 | 830(11.7) | 1 279(18.1) | 508(7.2) | 448(6.3) | 212(3.0) | 372(5.2) | 241(3.4) | 316(4.4) | 324(4.5) |
2018 | 541(9.1) | 781(13.1) | 368(6.2) | 458(7.7) | 144(2.4) | 208(3.5) | 164(2.7) | 118(1.9) | 191(3.2) |
2019 | 780(12.1) | 1 148(17.8) | 398(6.1) | 427(6.6) | 203(3.1) | 289(4.4) | 226(3.5) | 300(4.6) | 307(4.7) |
2020 | 536(9.3) | 824(14.3) | 516(8.9) | 439(7.6) | 122(2.1) | 191(3.3) | 141(2.4) | 229(3.9) | 183(3.1) |
Tab.2
Drug resistance of MTB clinical isolates to 9 anti-tuberculosis drugs in different age groups"
年龄段 | 耐INH | 耐Sm | 耐EMB | 耐RFP | 耐Km | 耐Pto | 耐Cm | 耐Ofx | 耐PAS |
---|---|---|---|---|---|---|---|---|---|
合计 | 4 333(11.0) | 6 320(16.1) | 2 748(7.0) | 2 750(6.9) | 1 143(2.9) | 1 579(4.0) | 1 253(3.2) | 1 698(4.3) | 1 499(3.8) |
≤ 18岁 | 98(7.7) | 189(14.8) | 77(6.0) | 80(6.3) | 32(2.5) | 37(2.9) | 28(2.2) | 44(3.5) | 44(3.5) |
19 ~ 59岁 | 3 127(11.0) | 4 700(16.6) | 1 947(6.9) | 1 943(6.8) | 758(2.6) | 1 104(3.9) | 846(3.0) | 1 099(3.8) | 971(3.4) |
≥ 60岁 | 1 108(11.5) | 1 431(14.9) | 724(7.5) | 682(7.1) | 353(3.6) | 438(4.5) | 379(3.9) | 555(5.7) | 484(5.0) |
Tab.3
Drug resistance of MTB clinical isolates by year"
年份 | 患者数量 | 单耐药 | 多耐药 | 耐多药 | 广泛耐药 | |||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
例数 | 率(%) | 例数 | 率(%) | 例数 | 率(%) | 例数 | 率(%) | |||||
合计 | 39 048 | 5 648 | 14.46 | 2 015 | 5.16 | 1 787 | 4.58 | 503 | 1.29 | |||
2014 | 2 856 | 399 | 13.97 | 159 | 5.57 | 170 | 5.95 | 59 | 2.07 | |||
2015 | 4 943 | 570 | 11.53 | 213 | 4.31 | 266 | 5.38 | 82 | 1.66 | |||
2016 | 6 087 | 939 | 15.43 | 296 | 4.86 | 282 | 4.63 | 70 | 1.15 | |||
2017 | 7 045 | 1 039 | 14.75 | 417 | 5.92 | 328 | 4.66 | 107 | 1.52 | |||
2018 | 5 930 | 929 | 15.67 | 298 | 5.03 | 171 | 2.88 | 21 | 0.35 | |||
2019 | 6 425 | 862 | 13.42 | 324 | 5.04 | 341 | 5.31 | 113 | 1.76 | |||
2020 | 5 762 | 910 | 15.79 | 308 | 5.35 | 229 | 3.97 | 51 | 0.89 |
1 |
BAGCCHI S. WHO's Global Tuberculosis Report 2022[J]. Lancet Microbe, 2023,4(1):e20. doi:10.1016/s2666-5247(22)00359-7
doi: 10.1016/s2666-5247(22)00359-7 |
2 |
CHEN Y, LIU J, ZHANG Q, et al.Epidemiological features and temporal trends of HIV-negative tuberculosis burden from 1990 to 2019: a retrospective analysis based on the Global Burden of Disease Study 2019[J]. BMJ Open, 2023,13(9):e074134. doi:10.1136/bmjopen-2023-074134
doi: 10.1136/bmjopen-2023-074134 |
3 |
DOMÍNGUEZ J, BOEREE M J, CAMBAU E,et al. TBnet and RESIST-TB networks. Clinical implications of molecular drug resistance testing for Mycobacterium tuberculosis: a 2023 TBnet/RESIST-TB consensus statement[J]. Lancet Infect Dis, 2023,23(4):e122-e137. doi:10.1016/s1473-3099(22)00875-1
doi: 10.1016/s1473-3099(22)00875-1 |
4 | 赵雁林, 逢宇. 结核病实验室检验规程[M]. 北京:人民卫生出版社, 2015:18-65. |
5 | World Health Organization. Technical manual for drug susceptibility testing of medicines used in the treatment of tuberculosis[M]. Global Tuberculosis Programme, 2018. |
6 |
VINEY K, LINH N N, GEGIA M, et al. New definitions of pre-extensively and extensively drug-resistant tuberculosis: update from the World Health Organization[J]. Eur Respir J, 2021,57(4):2100361. doi:10.1183/13993003.00361-2021
doi: 10.1183/13993003.00361-2021 |
7 | MENZIES R, HOPEWELL K, NUNN P, et al. Monitoring During Treatment in: Treatment of Tuberculosis Guidelines. 4 Ed[C]. TNO, 2010. |
8 | 田鹏,李娜娜,刘梅,等. 遵义地区303例肺结核患者微孔板药敏结果的耐药模式分析[J]. 遵义医科大学学报, 2023,46(7):684-691. |
9 | 马广仁,曹佳伟,林梅,等. 青岛市结核病患者2016-2021年结核分枝杆菌耐药情况分析[J]. 精准医学杂志, 2022,37(5):418-421. |
10 |
MUSHTAQ F, RAZA S M, AHMAD A, et al. Antimicrobial drug resistant features of Mycobacterium tuberculosis associated with treatment failure[J]. PLoS One, 2023,18(10):e0293194. doi:10.1371/journal.pone.0293194
doi: 10.1371/journal.pone.0293194 |
11 |
GHODOUSI A, TAGLIANI E, KARUNARATNE E, et al. Isoniazid Resistance in Mycobacterium tuberculosis Is a Heterogeneous Phenotype Composed of Overlapping MIC Distributions with Different Underlying Resistance Mechanisms[J]. Antimicrob Agents Chemother, 2019,63(7):e00092-19. doi:10.1128/aac.00092-19
doi: 10.1128/aac.00092-19 |
12 |
YUEN L K, LESLIE D, COLOE P J. Bacteriological and molecular analysis of rifampin-resistant Mycobacterium tuberculosis strains isolated in Australia[J]. J Clin Microbiol, 1999,37(12):3844-3850. doi:10.1128/jcm.37.12.3844-3850.1999
doi: 10.1128/jcm.37.12.3844-3850.1999 |
13 |
WILLIAMS D L, SPRING L, COLLINS L, et al. Contribution of rpoB mutations to development of rifamycin cross-resistance in Mycobacterium tuberculosis[J]. Antimicrob Agents Chemother, 1998,42(7):1853-1857. doi:10.1128/aac.42.7.1853
doi: 10.1128/aac.42.7.1853 |
14 |
REKART M L, AUNG A, CULLIP T, et al. Household drug-resistant TB contact tracing in Tajikistan[J]. Int J Tuberc Lung Dis, 2023,27(10):748-753. doi:10.5588/ijtld.23.0066
doi: 10.5588/ijtld.23.0066 |
15 |
VERMA A K, YADAV R N, KUMAR G, et al. Multidrug-resistant and extensively drug-resistant Mycobacterium tuberculosis strains in geriatrics: An analysis and its implications in tuberculosis control[J]. J Clin Tuberc Other Mycobact Dis, 2022,27:100317. doi:10.1016/j.jctube.2022.100317
doi: 10.1016/j.jctube.2022.100317 |
16 |
AN Q, SONG W, LIU J, et al. Primary Drug-Resistance Pattern and Trend in Elderly Tuberculosis Patients in Shandong, China, from 2004 to 2019[J]. Infect Drug Resist, 2020,13:4133-4145. doi:10.2147/idr.s277203
doi: 10.2147/idr.s277203 |
17 |
SHARLING L, MARKS S M, GOODMAN M, et al. Rifampin-resistant Tuberculosis in the United States, 1998-2014[J]. Clin Infect Dis, 2020,70(8):1596-1605. doi:10.1093/cid/ciz491
doi: 10.1093/cid/ciz491 |
18 |
ROELENS M, BATTISTA MIGLIORI G, ROZANOVA L, et al. Evidence-based Definition for Extensively Drug-Resistant Tuberculosis[J]. Am J Respir Crit Care Med, 2021,204(6):713-722. doi:10.1164/rccm.202009-3527oc
doi: 10.1164/rccm.202009-3527oc |
19 |
CHE Y, SONG Q, YANG T, et al. Fluoroquinolone resistance in multidrug-resistant Mycobacterium tuberculosis independent of fluoroquinolone use[J]. Eur Respir J, 2017,50(6):1701633. doi:10.1183/13993003.01633-2017
doi: 10.1183/13993003.01633-2017 |
20 |
MIRZAYEV F, VINEY K, LINH N N, et al. World Health Organization recommendations on the treatment of drug-resistant tuberculosis, 2020 update[J]. Eur Respir J, 2021,57(6):2003300. doi:10.1183/13993003.03300-2020
doi: 10.1183/13993003.03300-2020 |
21 |
HAMEED H M A, TAN Y, ISLAM M M, et al. Phenotypic and genotypic characterization of levofloxacin- and moxifloxacin-resistant Mycobacterium tuberculosis clinical isolates in southern China[J]. J Thorac Dis, 2019,11(11):4613-4625. doi:10.21037/jtd.2019.11.03
doi: 10.21037/jtd.2019.11.03 |
22 |
MODONGO C, BARILAR I, WANG Q, et al. Tuberculosis Variant with Rifampin Resistance Undetectable by Xpert MTB/RIF, Botswana[J]. Emerg Infect Dis, 2023,29(11):2403-2406. doi:10.3201/eid2911.230987
doi: 10.3201/eid2911.230987 |
[1] | Qi CHEN,Yaxi ZHANG,Mingxia ZHANG,Jieyun ZHANG,Qianting. YANG. The detection value of tuberculosis-specific QFT-TB in different types of specimens of tuberculosis patients [J]. The Journal of Practical Medicine, 2024, 40(7): 1002-1005. |
[2] | Xiaotong LIU,Xianhua SU,Zhijun XIN,Fengqiong GAO,Jiayi FENG,Tongxia. XIA. Risk factors of postoperative complications in patients with spinal tuberculosis and the predictive value of prognostic nutritional index [J]. The Journal of Practical Medicine, 2024, 40(7): 972-978. |
[3] | Yigang TAN,Haobin KUANG,Hongmei FU,Chunyan LI,Xiaobing ZHAO,Lijing XUE. Analysis of clinical characteristics of 33 cases of tuberculosis complicated by tumor necrosis factor⁃α inhibitor in autoimmune diseases [J]. The Journal of Practical Medicine, 2024, 40(3): 378-383. |
[4] | Linlin GAI,Weice SUN,Jinjin CHU,Donghua XU. Changes of M1/M2 macrophages polarization associated with active pulmonary tuberculosis and the effect of ESAT6 on macrophage polarization [J]. The Journal of Practical Medicine, 2024, 40(20): 2867-2873. |
[5] | Haojie TANG,Zilong YANG,Zhaoxian YU,Zhiyu FENG,Haiping DONG,Xiang LI,Wei ZHAO,Haobin. KUANG. Construction and evaluation of a risk prediction model for linezolid-related neurological adverse reactions in patients with multidrug-resistant tuberculosis [J]. The Journal of Practical Medicine, 2024, 40(19): 2690-2695. |
[6] | Shuyu ZHANG,Yuehong. LI. An overview of mycobacterium tuberculosis infection after kidney transplantation [J]. The Journal of Practical Medicine, 2024, 40(15): 2047-2050. |
[7] | Yigang TAN,Honglan ZHONG,Chunming LUO,Xingshan CAI,Bitong WU,Hui FAN,Min. SONG. Clinical analysis of pulmonary tuberculosis complicated with Nocardia farcinica [J]. The Journal of Practical Medicine, 2024, 40(14): 1969-1974. |
[8] | Jing GUI,Feng WANG,Hui YANG,Yumao CAI,Chuangyue. HONG. Investigation of oxidised low⁃density lipoprotein as a risk assessment indicator in patients with type 2 diabetes mellitus combined with pulmonary tuberculosis [J]. The Journal of Practical Medicine, 2024, 40(14): 1995-2002. |
[9] | Wendi ZHOU,Jiamin LIN,Daichen JU,Qi WANG,Jialou ZHU,Ning SU,Jinxing. HU. Proteomic profiling and functional analysis of differentially expressed proteins in lung cancer coexistent with pulmonary tuberculosis [J]. The Journal of Practical Medicine, 2024, 40(13): 1814-1821. |
[10] | Shengming YU,Lianghua XIA,Jiahuan ZHAN,Siqi LIU,Wei WANG,Liang YAN,Kaisen. CHEN. Study on the mutation characteristics of streptomycin genes of Multidrug-Resistant Mycobacterium Tuberculosis in Jiangxi Province [J]. The Journal of Practical Medicine, 2024, 40(1): 91-96. |
[11] | Gang LIU,Rushu LAN,Huifang QIN,Xiaoling QIN,Yixiang QIN,Ruolan XU,Dan. LUO. Mutation characteristics of ethambutol resistance gene of Mycobacterium tuberculosis in Guangxi [J]. The Journal of Practical Medicine, 2023, 39(24): 3261-3266. |
[12] | Nenhan WANG,Yanfeng ZHAO,Lili TIAN,Shuangshuang CHEN,Hao CHEN,Yixuan REN,Chuanyou LI,Xiaowei. DAI. Clinical application of fluorescence polymerase chain reaction probe melting curve technique in detecting isoniazid drug⁃resistance of Mycobacterium tuberculosis in sputum samples [J]. The Journal of Practical Medicine, 2023, 39(20): 2664-2670. |
[13] |
FU Xuefeng, LOU Siyu, PENG Zhangli..
Mycobacterium tuberculosis Rv3737 suppresses macrophage autophagy to enhance bacterial survival in macrophages [J]. The Journal of Practical Medicine, 2023, 39(2): 198-203. |
[14] |
LIU Zhenning, XU Yunyi, HU Lihuan, LIU Zhihui, HU Jinxing, LI Hua, GUAN Ping..
The clinical value of peripheral blood cell analysis and tuberculosis antibody detection in the diagnosis of pulmonary tuberculosis [J]. The Journal of Practical Medicine, 2023, 39(2): 262-266. |
[15] | Liang LI,Yuhong. LIU. Treatment course of sensitive tuberculosis: From 24 months to 2 months [J]. The Journal of Practical Medicine, 2023, 39(19): 2421-2423. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||